14 20 S
PIP/PIPW-B SURVEYS 2014 AND ANATOMIC PATHOLOGY EDUCATION PROGRAMS Performance Improvement Program in Surgical Pathology PARTICIPANT SUMMARY This document is available on e-LAB Solutions™. © 2014 College of American Pathologists. The College does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The College hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The College prohibits use of the material in the Report — and any unauthorized use of the College’s name or logo — in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The College will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the College’s name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. 2014 PIP/PIPW-B PARTICIPANT SUMMARY Program Update This report summarizes the diagnostic responses for set B of the 2014 Performance Improvement Program in Surgical Pathology (PIP & PIPW). A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only. SURGICAL PATHOLOGY COMMITTEE Philip A. Branton, MD FCAP, Chair Rochelle A. Simon, MD FCAP, Vice Chair Aleodor Alexandru Andea, MBA, MD FCAP Aaron Auerbach, MD FCAP Brad B. Bryan, MD FCAP Simion Ion Chiosea, MD FCAP William V. Chopp, MD FCAP Amy M. Coffey, MD-J Byron E. Crawford, MD FCAP H. Parry Dilworth, MD FCAP Julie C. Fanburg-Smith, MD FCAP Alyssa M. Krasinskas, MD FCAP Tamera J. Lillemoe, MD FCAP Daniel J. Luthringer, MD FCAP Marisa Rose Nucci, MD FCAP Nilsa C. Ramirez, MD FCAP Kirtee Raparia, MD FCAP Vijaya B. Reddy MD, MBA FCAP Thomas S. Winokur, MD FCAP Diagnosis (2858) Hepatic epithelioid hemangioendothelioma Case # 2014-11 Code 2056 1008 1872 2858 2859 1730 Diagnosis Angiosarcoma Cholangiocarcinoma Cirrhosis Hepatic epithelioid hemangioendothelioma Metastatic signet ring cell carcinoma Sclerosed hemangioma PIP Participants No. % PIPW Participants No. % 131 70 19 5699 2.2 1.2 0.3 95.6 4 6 3.6 5.5 4 91 3.6 82.7 10 28 0.2 0.5 1 4 1.0 3.6 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2559 1405 1434 147 10 46.0 25.3 25.8 2.7 0.2 Diagnosis (2702) Familial adenomatous polyposis Case # 2014-12 Code Diagnosis 2702 2860 2703 2861 Familial adenomatous polyposis Juvenile polyposis syndrome Lynch syndrome MUTYH-associated polyposis 2862 Sporadic adenomas PIP Participants No. % PIPW Participants No. % 5918 31 11 - 99.3 0.5 0.2 - 104 2 1 1 96.3 1.9 0.9 0.9 - - 0 0.0 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2382 1329 1538 247 17 43.2 24.1 27.9 4.5 0.3 Diagnosis (2383) Seminoma Case # 2014-13 Code 1994 2470 2383 2341 2271 2863 Diagnosis Embryonal carcinoma Malignant lymphoma Seminoma Sertoli cell tumor Spermatocytic seminoma Yolk sac tumor, solid pattern PIP Participants No. % 15 6 5900 11 22 4 0.3 0.1 99.0 0.2 0.3 0.1 PIPW Participants No. % 0 1 96 0 7 0 0.0 1.0 92.3 0.0 6.7 0.0 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2484 1370 1510 164 20 44.7 24.7 27.2 3.0 0.4 Diagnosis (1486) Cellular schwannoma Case # 2014-14 Code 1486 2864 2159 2359 1647 2865 1584 2068 Diagnosis Cellular schwannoma Classic schwannoma Malignant peripheral nerve sheath tumor Neurofibroma Sarcomatoid carcinoma Solitary fibrous tumor, malignant Spindle cell melanoma Synovial sarcoma PIP Participants No. % 5503 325 27 12 2 65 0 19 92.4 5.4 0.5 0.2 0.1 1.1 0.0 0.3 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2485 1422 1477 121 14 45.0 25.8 26.7 2.2 0.3 PIPW Participants No. % 52 27 1 6 0 17 0 0 50.5 26.2 1.0 5.8 0.0 16.5 0.0 0.0 Diagnosis (2070) Endometrioid carcinoma Case # 2014-15 Code Diagnosis 2216 Clear cell carcinoma 2070 2866 Endometrioid carcinoma Mucinous carcinoma/serous carcinoma PIP Participants No. % 86 5858 11 1.4 98.4 0.2 PIPW Participants No. % 0 0.0 99 2 98.0 2.0 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2428 1364 1505 207 24 44.0 24.7 27.2 3.7 0.4 Diagnosis (1698) Aggressive angiomyxoma Case # 2014-16 Code 1698 1906 1752 1372 2867 1509 Diagnosis Aggressive angiomyxoma Angiomyofibroblastoma Cellular angiofibroma Fibroepithelial stromal polyp Massive vulval edema Superficial angiomyxoma PIP Participants No. % 5829 36 12 7 14 55 98.0 0.6 0.2 0.1 0.2 0.9 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2402 1395 1494 169 27 43.8 25.4 27.2 3.1 0.5 PIPW Participants No. % 87 2 1 1 1 7 87.9 2.0 1.0 1.0 1.0 7.1 Diagnosis (2060) Littoral cell angioma Case # 2014-17 Code 1630 2060 2868 2869 1546 2870 Diagnosis Hairy cell leukemia Littoral cell angioma Sclerosing angiomatoid nodular transformation Splenic angiosarcoma Splenic hemangioma Splenic lymphangioma PIP Participants No. % PIPW Participants No. % 12 5685 55 0.2 95.6 0.9 2 68 11 2.1 70.8 11.5 8 171 18 0.1 2.9 0.3 2 12 1 2.1 12.5 1.0 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2320 1434 1542 174 21 42.2 26.1 28.1 3.2 0.4 Diagnosis (1990) Splenic marginal zone lymphoma Code Case # 2014-18 2643 1800 1630 2408 2334 1990 2871 Diagnosis Chronic lymphocytic leukemia/small lymphocytic lymphoma Follicular lymphoma Hairy cell leukemia Hepatosplenic T-cell lymphoma Mantle cell lymphoma Splenic marginal zone lymphoma T-cell large granular lymphocytic leukemia PIP Participants No. % 26 0.4 5 5.3 17 110 8 82 5700 3 0.3 1.9 0.1 1.4 95.8 0.1 1 19 1 6 63 0 1.0 20.0 1.0 6.3 66.4 0.0 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIPW Participants No. % PIP Participants No. % 2391 1452 1490 123 9 43.6 26.6 27.3 2.3 0.2 Diagnosis (2216) Clear cell carcinoma Case # 2014-19 Code 2216 2461 2462 2465 2377 2467 Diagnosis Clear cell carcinoma Dysgerminoma Krukenberg tumor Metastatic renal cell carcinoma Serous borderline tumor Yolk sac tumor PIP Participants No. % PIPW Participants No. % 5736 8 96.4 0.1 74 1 78.0 1.0 4 7 178 17 0.1 0.1 3.0 0.3 2 1 17 0 2.0 1.0 18.0 0.0 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2401 1389 1522 170 19 43.5 25.3 27.7 3.1 0.4 Diagnosis (2873) Nephroblastoma (Wilms tumor) Case # 2014-20 Code 2743 2872 1666 2873 2320 1317 Diagnosis Clear cell sarcoma Lymphoma/leukemia Metanephric adenoma Nephroblastoma (Wilms tumor) Primitive neuroectodermal tumor Rhabdoid tumor PIP Participants No. % 12 1 9 5831 81 6 0.2 0.1 0.2 98.0 1.4 0.1 Technical Quality of Slide Rating 001 002 003 004 005 Glass Slide Evaluation Excellent Satisfactory Unsatisfactory PIP Participants No. % 2697 1263 1385 115 15 49.2 23.1 25.3 2.1 0.3 PIPW Participants No. % 4 0 1 70 15 3 4.3 0.0 1.1 75.3 16.1 3.2
© Copyright 2024